Shitara, Kohei http://orcid.org/0000-0001-5196-3630
Bang, Yung-Jue http://orcid.org/0000-0001-6000-4597
Iwasa, Satoru
Sugimoto, Naotoshi
Ryu, Min-Hee http://orcid.org/0000-0002-1033-1263
Sakai, Daisuke
Chung, Hyun Cheol
Kawakami, Hisato http://orcid.org/0000-0002-3280-4850
Yabusaki, Hiroshi
Sakamoto, Yasuhiro
Nishina, Tomohiro
Inaki, Koichiro
Kuwahara, Yusuke http://orcid.org/0009-0000-2912-7273
Wada, Naoya
Suto, Fumitaka http://orcid.org/0009-0009-5649-2650
Arita, Takeo
Sugihara, Masahiro
Tsuchihashi, Zenta
Saito, Kaku
Kojima, Akihito
Yamaguchi, Kensei
Funding for this research was provided by:
This study was funded by Daiichi Sankyo and AstraZeneca
Article History
Received: 9 November 2023
Accepted: 11 April 2024
First Online: 14 May 2024
Competing interests
: K. Shitara reports receiving personal fees for consulting and advisory roles from Bristol Myers Squibb, Takeda, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Merck Pharmaceutical, Astellas, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals, ALX Oncology Inc. and Bayer; receiving honoraria from Bristol Myers Squibb, Ono Pharmaceutical, Janssen, Eli Lilly, Astellas and AstraZeneca; and receiving research funding (all to institution) from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Amgen, Eisai, PRA Health Sciences and Syneos Health, outside the submitted work within the past 36 months. Y.-J.B. reports study funding and medical writing/editing support from Daiichi Sankyo since initial planning of the work; grants from Roche/Genentech, Merck Serono, Astellas, MSD, Amgen and BeiGene; and consulting fees from MSD, Daiichi Sankyo, ALX Oncology, Hanmi, Merck Serono, Astellas, Samyang Biopharm and Daewoong Pharmaceutical in the past 36 months. S.I. reports research funding to his institution from Daiichi Sankyo since initial planning of the work and in the past 36 months. N.S., D.S., H.C.C., H.Y., Y.S. and M.-H.R. report consulting fees and payment or honoraria from Daiichi Sankyo and AstraZeneca in the past 36 months. H.K. reports grants or contracts from Chugai Pharmaceutical Co. Ltd, Kobayashi Pharmaceutical Co. Ltd, Taiho Pharmaceutical Co. Ltd and Eisai Co. Ltd, and payment or honoraria from Bristol Myers Squibb Ltd, Eli Lilly Japan K.K., Ono Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd, Takeda Pharmaceutical Co. Ltd, Teijin Pharma Ltd, GlaxoSmithKline K.K., Bayer Yakuhin Ltd, BSD K.K., Chugai Pharmaceutical Co. Ltd, Merck Biopharma Co. Ltd, Yakult Pharmaceutical Industry Co. Ltd, Taiho Pharmaceutical Co. Ltd and Otsuka Pharmaceutical Co. Ltd within the past 36 months. T.N. reports payment or honoraria from Daiichi Sankyo Pharma, Ono Pharmaceutical, Bristol Myers Squibb, Eli Lilly, Takeda Pharmaceutical, Chugai Pharmaceutical, Merck Serono, Taiho Pharmaceutical and Yakult Honsha, and was a member of the data safety monitoring board for Janssen Pharmaceuticals in the past 36 months. Z.T. is an employee of Daiichi Sankyo Inc. and owns restricted stocks in Daiichi Sankyo. T.A. is an employee of Daiichi Sankyo Co. Ltd and reports support for medical writing from Daiichi Sankyo Co. Ltd since initial planning of the work. A.K. and M.S. are employees of Daiichi Sankyo Co. Ltd. Y.K., F.S. and K. Saito are current employees of Daiichi Sankyo Inc. and were previously employed by Daiichi Sankyo Co. Ltd. K.I. and N.W. are employees of Daiichi Sankyo RD Novare Co. Ltd and contributed to work with Daiichi Sankyo Co. Ltd. K.Y. reports funding for the present manuscript from Daiichi Sankyo since the initial planning of the work, and payment or honoraria from Daiichi Sankyo, Eli Lilly Japan K.K., Bristol Myers Squibb, Merck Biopharm, Taiho and Chugai in the past 36 months.